Zymeworks Inc. · NASDAQ:ZYME
Zymeworks — 2017 UBS Global Healthcare Conference
33 slides from Zymeworks's conference presentation, Jun 22, 2017
Slide 1: Zymeworks Corporate Overview - 2017 UBS Global Healthcare Conference
ZYMEWORKS CORPORATE OVERVIEW 2017 UBS GLOBAL HEALTHCARE CONFERENCE
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes “forward-looking statements” within the meaning of U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-looking statemen
Slide 3: A Clinical-Stage Biopharmaceutical Company Developing Multifunctional Therapeutics for Oncology
A Clinical-Stage Biopharmaceutical Company Developing Fit-for-Purpose, Multifunctional Therapeutics for Oncology Complementary Next-Generation Platforms Azymetric™ ZymeLink™ EFECT™ AlbuCORE™ Marquee Strategic Partnerships Wholly-Owned ZW25: Bispecific antibody in Phase 1 for HER2-expressing cancers
Slide 4: 2016: A Transformative Year
2016: A Transformative Year ZW25 Granted Orphan Initiated Phase 1 Drug Designations Clinical Trial ZW25 ZW33 Two new pharma Research milestone Acquisition of collaborations received ZymeLink™ ADC Platform $61.5 Million Zymeworks’ Crossover Opportunity COMPANY OF THE YEAR 115+ Employees Round Buildin
Slide 5: Table of Contents
Table of Contents 1 Therapeutic Platforms and Integrated Drug Development Engine 2 Strategic Partnerships with Global Pharmaceutical Companies 3 Wholly-Owned Clinical Pipeline 4 Anticipated Near-Term Catalysts for Lead Product Candidates 5 Financial Highlights 6 Experienced Management Team and Robus
Slide 6: Next-Generation Therapeutic Platforms
Next-Generation Therapeutic Platforms ™ ™ ™ ™ PAGE 6
Slide 7: Complementary Therapeutic Platforms
Complementary Therapeutic Platforms Flexibility to engineer fit-for-purpose biotherapeutics to maximize therapeutic effect Azymetric Bispecifics™ ZymeLink™ AlbuCORE™ Bispecific Fab Hybrid Alternate Drug Antibody- Formats Formats Formats Conjugates Alternatives EFECT™ Immune Modulation PAGE 7
Slide 8: Zymeworks' Fully Integrated Drug Development Engine
Zymeworks’ Fully Integrated Drug Development Engine Inhibition of Potent Multiple ADC Pathways Payloads Biparatopic- Dual- Enhanced Targeting Payload of Receptors Complementary Delivery Target Discovery, Therapeutic Platforms Highly- Selection and Customized Antibody Azymetric™ ZymeLink™ Fit-for-Pur
Slide 9: Table of Contents
Table of Contents 1 Therapeutic Platforms and Integrated Drug Development Engine 2 Strategic Partnerships with Global Pharmaceutical Companies 3 Wholly-Owned Clinical Pipeline 4 Anticipated Near-Term Catalysts for Lead Product Candidates 5 Financial Highlights 6 Experienced Management Team and Robus
Slide 10: Strategic Partnerships and Collaborations
Strategic Partnerships and Collaborations Remaining Enabling Potential Milestones Partners Events Programs Platform(s) ($ millions US) Announced:2011 Milestone #1: 2012 Multiple AzymetricTM 186 Milestone #2: 2013 Up to 3 EFECTTM Expanded: 2014 Announced: 2014 Multiple Expanded: 2014 Up to 4 Azymetri
Slide 11: Flexible Platforms Will Allow Further Pipeline Expansion
Zymeworks’ Flexible Platforms Will Allow Further Pipeline Expansion and Broader Therapeutic Area Applications Future Autoimmune Inflammation Today Broader Oncology Broader Oncology Underserved Underserved Underserved Oncology Oncology Oncology Multiple Active Future Discovery ZW25 & ZW33 Discovery P
Slide 12: Table of Contents
Table of Contents 1 Therapeutic Platforms and Integrated Drug Development Engine 2 Strategic Partnerships with Global Pharmaceutical Companies 3 Wholly-Owned Clinical Pipeline 4 Anticipated Near-Term Catalysts for Lead Product Candidates 5 Financial Highlights 6 Experienced Management Team and Robus
Slide 13: Zymeworks' Wholly-Owned Product Candidates and Discovery Programs
Zymeworks’ Wholly-Owned Product Candidates and Discovery Programs PAGE 13
Slide 14: ZW25 – Bispecific for HER2-Expressing Cancers
ZW25 – Bispecific for HER2-Expressing Cancers Preliminary Anti-Tumor Activity at ASCO 2017 • Biparatopic - targets two distinct HER2 epitopes Unique • Increased binding density Mechanisms • Enhanced effector-mediated cytotoxicity of Action • Blocks ligand-dependent and -independent tumor growth • En
Slide 15: ZW25 – Biparatopic HER2 Binding Drives Unique Mechanisms of Action
ZW25 – Bispecific for HER2-Expressing Cancers Biparatopic HER2 Binding Drives Unique Mechanisms of Action • ZW25 targets two distinct HER2 epitopes (biparatopic) leading to unique binding geometries • Biparatopic Trans Binding – Each HER2 receptor can be targeted by two ZW25 antibodies • Monoclonal
Slide 16: ZW25 – Unique Binding Geometries
ZW25 – Bispecific for HER2-Expressing Cancers Biparatopic HER2 Binding Drives Unique Mechanisms of Action • ZW25’s unique binding geometries promote: • Extended chain formation and HER2 receptor clustering • Enhanced HER2 internalization and downregulation • Increased tumor cell binding density and
Slide 17: HER2 Classification for Breast Cancer
HER2 Classification for Breast Cancer HER2 HER2 HER2 HER2 HER2 Status High Intermediate Low Negative HER2 High 15.2% HER2 Intermediate IHC 2+, IHC 3+, IHC FISH IHC 1+, FISH 25.9% HER2 Assay IHC 0 or FISH Results 2+ or FISH Equivocal Equivocal or Negative HER2 Negative Positive or FISH FISH Negative
Slide 18: ZW25 – Adaptive Clinical Trial Design
ZW25 – Adaptive Clinical Trial Design Phase 1 Top-Line Data in Q1 2017 2016 2017 Q3 Q4 Q1 Q2 Q3 Q4 Phase 1 Phase 1 Trial Details First-in-human, open-label dose escalation and Dose Escalation expansion cohort studies 5;10;15 mg/kg • Patient Eligibility: Locally-advanced (unresectable) or metastatic
Slide 19: ZW25 – Preliminary Anti-Tumor Activity
ZW25 – Preliminary Anti-Tumor Activity Maximum Change in Tumor Size In Patients with Measurable Disease as of Feb 15 2017 60 5 mg/kg % Change in Target Lesions 40 10 mg/kg 20 15 mg/kg 0 * -20 * -40 -60 Gastric Breast Breast Esophageal Gastric Breast Breast Patient Diagnosis *PD due to new lesion PAG
Slide 20: ZW25 – Preliminary Anti-Tumor Activity Snapshot
ZW25 – Preliminary Anti-Tumor Activity Snapshot from the clinical database as of Feb 15 2017 Patient Prior HER2 Cohort Best Tumor Response Status Diagnosis Treatments Partial Response Breast H, P, K, L Active 55% ↓ in target lesions Partial Response Breast H, P, K, L Active 33% ↓ in target lesions P
Slide 21: ZW25 – Cohort Expansion and Registrational Path
ZW25 – Adaptive Clinical Trial Design Phase 1 Cohort Expansion and Registrational Path 2016 2017 2018 2019 2020 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Phase 1 Single Agent Cohort Expansion Dose Escalation 5;10;15 mg/kg Chemo Combo Cohort Expansion Registrational Single Agent Phase 2 Top-Lin
Slide 22: ZW25 – FDA-Granted Orphan Designation for Gastric and Ovarian Cancer
ZW25 – FDA-Granted Orphan Designation for Gastric and Ovarian Cancer HER2-High Gastric Cancer PDX HER2-High Ovarian Cancer CDX PAGE 22
Slide 23: ZW33 – Bispecific ADC for HER2-Expressing Cancers
ZW33 – Bispecific ADC for HER2-Expressing Cancers Phase 1 Trial Initiation in H2 2017 • Biparatopic - targets two distinct HER2 epitopes Unique • Increased binding density Mechanisms • Enhanced HER2 internalization to of Action • deliver a potent cytotoxin • down-regulate HER2 signaling Superior ant
Slide 24: ZW33 Efficacy in Trastuzumab-Resistant Breast Cancer PDX
ZW33 – Anti-HER2 Biparatopic Bispecific ADC Efficacy Trastuzumab-Resistant HER2-High Breast Cancer PDX • ZW33* demonstrates superior tumor growth inhibition as compared to other HER2-targeted therapies *prior to affinity optimization PAGE 24
Slide 25: ZW33 Efficacy in Ovarian Cancer PDX
ZW33 – Anti-HER2 Biparatopic Bispecific ADC Efficacy HER2-Expressing Ovarian Cancer PDX • Treatment with ZW33 promotes complete responses ZW33 T-DM1 Efficacy Criteria (n=10) (n=10) Tumor Growth Inhibition (%) 313% 65% 3D RECIST Scores Complete Response 8 0 Partial Response 2 1 Stable Disease - 3 Pro
Slide 26: Table of Contents
Table of Contents 1 Therapeutic Platforms and Integrated Drug Development Engine 2 Strategic Partnerships with Global Pharmaceutical Companies 3 Wholly-Owned Clinical Pipeline 4 Anticipated Near-Term Catalysts for Lead Product Candidates 5 Financial Highlights 6 Experienced Management Team and Robus
Slide 27: Upcoming Milestones
Upcoming Milestones 2017 Milestones q ZW25: Top-line data from the dose escalation portion of Phase 1 clinical trial (Q1 2017) q ZW25: Safety and preliminary anti-tumor activity data at ASCO (June 2017) q ZW33: Initiate Phase 1 clinical trial (H2 2017) q ZW33: Top-line Phase 1 data (Q1 2018) 201
Slide 28: Table of Contents
Table of Contents 1 Therapeutic Platforms and Integrated Drug Development Engine 2 Strategic Partnerships with Global Pharmaceutical Companies 3 Wholly-Owned Clinical Pipeline 4 Anticipated Near-Term Catalysts for Lead Product Candidates 5 Financial Highlights 6 Experienced Management Team and Robus
Slide 29: IPO Summary
IPO Summary Issuer Zymeworks Inc. Ticker/Exchange ZYME/NYSE & TSX Dual Listing Shares Offered 4,500,000 shares (100% primary) Over-Allotment Option 15% (100% primary) Offering Price $13.00 Gross Proceeds $58,500,000 Use of Proceeds Fund clinical development expenses for ZW25 and ZW33, repay outstand
Slide 30: Table of Contents
Table of Contents 1 Therapeutic Platforms and Integrated Drug Development Engine 2 Strategic Partnerships with Global Pharmaceutical Companies 3 Wholly-Owned Clinical Pipeline 4 Anticipated Near-Term Catalysts for Lead Product Candidates 5 Financial Highlights 6 Experienced Management Team and Robus
Slide 31: Zymeworks Management Team
Zymeworks Management Team Ali Tehrani, Ph.D. Founded Zymeworks in 2003. Current Board member of LifeSciences BC, Creatus Biosciences President & Chief Executive Officer Inc., CQDM and a member of the BC Premier’s Tech Council. Past member of the MITACS and BIOTECanada Advisory Boards and Committees.
Slide 32: Zymeworks Board of Directors
Zymeworks Board of Directors Nick Bedford Independent consultant. Former Chairman of the Board of ActiveState Corp. and Head of Chairman German Equities at UBS Noel Hall Independent consultant. Co-founder and former President of Aspreva Pharmaceuticals (acquired by Galenica) Kenneth J. Hillan, M.B.,
Slide 33: Zymeworks Corporate Overview
ZYMEWORKS CORPORATE OVERVIEW